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Graphene oxide as a nanocarrier for controlled release and targeted delivery of an 
anticancer active agent, chlorogenic acid 
ABSTRACT 
We have synthesized graphene oxide using improved Hummer's method in order to explore 
the potential use of the resulting graphene oxide as a nanocarrier for an active anticancer 
agent, chlorogenic acid (CA). The synthesized graphene oxide and chlorogenic acid-graphene 
oxide nanocomposite (CAGO) were characterized using Fourier transform infrared (FTIR) 
spectroscopy, thermogravimetry and differential thermogravimetry analysis, Raman 
spectroscopy, powder X-ray diffraction (PXRD), UV–vis spectroscopy and high resolution 
transmission electron microscopy (HRTEM) techniques. The successful conjugation of 
chlorogenic acid onto graphene oxide through hydrogen bonding and π–π interaction was 
confirmed by Raman spectroscopy, FTIR analysis and X-ray diffraction patterns. The loading 
of CA in the nanohybrid was estimated to be around 13.1% by UV–vis spectroscopy. The 
release profiles showed favourable, sustained and pH-dependent release of CA from CAGO 
nanocomposite and conformed well to the pseudo-second order kinetic model. Furthermore, 
the designed anticancer nanohybrid was thermally more stable than its counterpart. The in 
vitro cytotoxicity results revealed insignificant toxicity effect towards normal cell line, with a 
viability of > 80% even at higher concentration of 50 μg/mL. Contrarily, CAGO 
nanocomposite revealed enhanced toxic effect towards evaluated cancer cell lines (HepG2 
human liver hepatocellular carcinoma cell line, A549 human lung adenocarcinoma epithelial 
cell line, and HeLa human cervical cancer cell line) compared to its free form. 
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